(Q38058413)

23135217

27 August 2017

title

Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. (English)

1 reference

27 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

14 May 2020

Guy Brusselle

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

14 May 2020

2

Barbara Yawn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

14 May 2020

author name string

Andrea Rossi

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

14 May 2020

language of work or name

1 reference

1 March 2013

1 reference

23135217

Primary care respiratory journal : journal of the General Practice Airways Group

27 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

14 May 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

14 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

14 May 2020

page(s)

92-100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

How far is real life from COPD therapy guidelines? An Italian observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

New insights into the immunology of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

The aging immune system and its relationship to the development of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Future treatments for chronic obstructive pulmonary disease and its comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Molecular mechanisms of corticosteroid resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Methodological issues in therapeutic trials of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Is sustained pharmacologic lung volume reduction now possible in COPD?

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Changes in forced expiratory volume in 1 second over time in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Effect of tiotropium on quality of life in COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Glucocorticoid resistance in inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Pharmacotherapy and the risk for community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Reported pneumonia in patients with COPD: findings from the INSPIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Glucocorticoid use, other associated factors, and the risk of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Long-term therapy in COPD: any evidence of adverse effect on bone?

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Clinical practice. Osteoporosis in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Use of inhaled corticosteroids and the risk of cataracts.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Association of inhaled corticosteroid use with cataract extraction in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

A population based case-control study of cataract and inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Contemporary management of chronic obstructive pulmonary disease: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Withdrawal of inhaled corticosteroids in individuals with COPD--a systematic review and comment on trial methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Prevention of Death in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4104%2FPCRJ.2012.00092

Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group

21 January 2018

1 reference

12 December 2020

Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease

1 reference

12 December 2020

Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment

1 reference

12 December 2020

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

12 December 2020

Low-dose inhaled and nasal corticosteroid use and the risk of cataracts

1 reference

12 December 2020

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

12 December 2020

Treating COPD--the TORCH trial, P values, and the Dodo

1 reference

12 December 2020

Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia

1 reference

12 December 2020

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

1 reference

12 December 2020

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

12 December 2020

Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

1 reference

12 December 2020

Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10-year period

1 reference

12 December 2020

Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study

1 reference

12 December 2020

Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study

1 reference

12 December 2020

Inhaled corticosteroids in COPD: the case against

1 reference

12 December 2020

Spirometry in primary care case-identification, diagnosis and management of COPD

1 reference

12 December 2020

Thinning bone and inhaled corticosteroid in COPD: what to do until there is definitive proof?

1 reference

12 December 2020

[COPD routine management in France: are guidelines used in clinical practice?]

1 reference

12 December 2020

General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study

1 reference

12 December 2020

Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures

1 reference

12 December 2020

Inhaled Corticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases

1 reference

12 December 2020

COPD, bone metabolism, and osteoporosis

1 reference

12 December 2020

Guideline for the management of chronic obstructive pulmonary disease--2011 update.

1 reference

12 December 2020

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

1 reference

12 December 2020

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease

1 reference

12 December 2020

Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database

1 reference

12 December 2020

Quality of life changes in COPD patients treated with salmeterol

1 reference

12 December 2020

Identifiers

DOI

10.4104/PCRJ.2012.00092

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

Dimensions Publication ID

14 May 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json

14 May 2020

23135217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6548052&resulttype=core&format=json